Kringle Pharma Beheer

Beheer criteriumcontroles 1/4

De CEO Kringle Pharma is Kiichi Adachi, benoemd in Dec2016, heeft een ambtstermijn van 7.92 jaar. bezit rechtstreeks 1.12% van de aandelen van het bedrijf, ter waarde ¥ 62.47M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 5.9 jaar.

Belangrijke informatie

Kiichi Adachi

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.9yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	5.9yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02

CEO

Kiichi Adachi (57 yo)

7.9yrs

Tenure

Kiichi Adachi, Ph D., has been President at Kringle Pharma, Inc since December 27, 2016. Kiichi Adachi serves as a Director of Kringle Pharma, Inc. since December 2005.Kiichi Adachi was Research Scientist...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kiichi Adachi	President & Director	7.9yrs	geen gegevens	1.12% ¥ 62.5m
Tomoya Shimojo	Chief Financial Officer & Director of Accounting and Corporate Planning	no data	geen gegevens	geen gegevens
Kunio Matsumoto	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Koichi Murakami	GM of Corporate Planning Management Department & Director	no data	geen gegevens	geen gegevens
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	geen gegevens	geen gegevens
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4884 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kiichi Adachi	President & Director	18.9yrs	geen gegevens	1.12% ¥ 62.5m
Koichi Murakami	GM of Corporate Planning Management Department & Director	2.9yrs	geen gegevens	geen gegevens
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	geen gegevens	geen gegevens
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	geen gegevens	geen gegevens
Kohichiro Yoshino	Independent Outside Director	5.9yrs	geen gegevens	geen gegevens
Akihiro Tomoyasu	Part Time Director	7.9yrs	geen gegevens	geen gegevens
Kazuto Ninomiya	Audit & Supervisory Board Member	5.9yrs	geen gegevens	geen gegevens
Masahiro Motokawa	Audit & Supervisory Board Member	5.9yrs	geen gegevens	geen gegevens
Yosuke Yamaguchi	Audit & Supervisory Board Member	5.9yrs	geen gegevens	geen gegevens
Masato Fukui	Independent Outside Director	3.9yrs	geen gegevens	geen gegevens

5.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4884 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.9 jaar).

Kringle Pharma Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

No independent directors

Recent updates

Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024

Kringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024

Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)

First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)

Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar

Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023

Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023

Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

Kringle Pharma, Inc. Submits Clinical Trial Application

Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University

Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022

Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)

Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)

Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

No independent directors

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022

Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of Als

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021

Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021

Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021

Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd